Misplaced Pages

Saridegib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from IPI-926) Experimental drug
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Saridegib" – news · newspapers · books · scholar · JSTOR (February 2016) (Learn how and when to remove this message)
Saridegib
Names
IUPAC name N-methanesulfonamide
Systematic IUPAC name N-pyridine-2,9′-naphthoazulen]-3′-yl]methanesulfonamide
Other names saridegib
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
IUPHAR/BPS
KEGG
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1Key: HZLFFNCLTRVYJG-WWGOJCOQSA-N
SMILES
  • C1C2((3(O2)CC45CC6C(CC6(5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
Properties
Chemical formula C29H48N2O3S
Molar mass 504.77 g·mol
Pharmacology
Routes of
administration 		Oral
Legal status
  • Investigational
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma. IPI-926 exhibits its pharmacological effect by inhibition of the G protein-coupled receptor smoothened, a component of the hedgehog signaling pathway. Chemically, it is a semi-synthetic derivative of the alkaloid cyclopamine. The process begins with cyclopamine extracted from harvested Veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making IPI-926 the only compound in development/testing that is not fully synthetic.

Saridegib is a member of a class of anti-cancer compounds known as hedgehog pathway inhibitors.

References

  1. "Pipeline: IPI-926". Infinity Pharmaceuticals. Archived from the original on 2012-01-19.
  2. ^ Tremblay, MR; Lescarbeau, A; Grogan, MJ; Tan, E; Lin, G; Austad, BC; Yu, LC; Behnke, ML; et al. (2009). "Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)". Journal of Medicinal Chemistry. 52 (14): 4400–18. doi:10.1021/jm900305z. PMID 19522463.
Categories: